Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State
MWN-AI** Summary
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) has announced a significant expansion of its U.S. commercial operations through the deployment of its FDA-cleared INSPIRA™ ART100 system at a new prestigious academic medical center in New York, which is ranked among the top 10 hospitals in the state according to Newsweek's World’s Best Hospitals 2025 ranking. This strategic move not only enhances Inspira's footprint within the Tier-1 hospital market in the U.S. but also signifies the growing acceptance and integration of its advanced life-support technologies within leading healthcare institutions.
The ART100 system has been integrated into the clinical workflow of the institution, designed to facilitate a structured evaluation aimed at developing clinical protocols and assessing potential wider adoption across the organization. This effort builds on the company’s existing FDA clearance and previous commercial engagements at other marquee U.S. healthcare facilities.
Mike Hershkovitz, Global VP Sales at Inspira Technologies, emphasized that this deployment is a pivotal advancement in the company's U.S. commercial strategy, underscoring the ART100's ability to meet the operational and clinical needs of top-tier healthcare providers. He expressed confidence in converting these evaluations into a sustainable commercial pipeline, indicating a commitment to further bolster its presence in key U.S. markets.
As a commercial-stage medical device company, Inspira Technologies specializes in advanced respiratory support and blood monitoring solutions, including plans for its next-generation ART500 system. With multiple cleared products, a robust IP portfolio, and a strategic focus on operational efficiency, Inspira is well-positioned to strengthen its role in the life-support and MedTech sectors.
MWN-AI** Analysis
Inspira Technologies’ recent deployment of its INSPIRA™ ART100 system at a top-tier New York academic medical center marks a significant milestone in its U.S. commercial expansion strategy. This initiative aligns with the company's goal of penetrating the immensely competitive Tier-1 U.S. healthcare market. The ART100, which has received FDA clearance, is designed for advanced respiratory support in cardiopulmonary procedures and positions Inspira as a strong player in the MedTech landscape.
Investors should view this development positively, as it signifies strengthening institutional relationships and market validation for the ART100. Deployment in a premier facility mirrors institutional trust in the product's efficacy and underscores a growing demand for advanced life-support solutions. Furthermore, Mike Hershkovitz’s comments on converting high-profile evaluations into a sustainable commercial pipeline highlight the company’s proactive approach to driving future revenue growth.
As the ART100 is integrated into clinical workflows, there is a potential for significant adoption and scale across multiple high-volume hospitals, should evaluations yield favorable results. The ability to pivot from initial evaluations to broader institutional integration can catalyze increased sales and provide a favorable return on investment.
However, investors should remain mindful of the inherent risks associated with forward-looking statements, including regulatory challenges and the competitive landscape. The success of the ART100 is contingent upon sustained positive clinical evaluations and effective execution of the company's commercial strategy.
Increased market interest could lead to positive stock momentum for Inspira Technologies (NASDAQ: IINN, IINNW). Investors are encouraged to closely monitor the progress of the ART100 evaluations and consider the overall trajectory of the company's product pipeline, including future innovations like the INSPIRA ART500. As always, an analysis of existing risk factors, as outlined in its SEC filings, should inform any investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
RA'ANANA, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and Drug Administration (“FDA”)-cleared INSPIRA™ ART100 system (the “ART100”) at a new and additional leading U.S. academic medical center.
The partnering institution is a prominent health system serving a large patient population, and is ranked among New York State’s top 10 hospitals in Newsweek’s World’s Best Hospitals 2025 ranking.
This deployment expands Inspira Technologies’ presence within the Tier-1 U.S. hospital market. The ART100 system has been integrated into the center’s clinical workflow to support a structured evaluation designed to define clinical protocols and potential broader institutional adoption. This activity builds upon the Company’s FDA clearance and ongoing commercial activity at other leading U.S. healthcare facilities.
Mike Hershkovitz, Global VP Sales at Inspira Technologies, commented: “This deployment represents a continued execution of our U.S. commercial strategy. Following our recent interaction with other leading healthcare providers, entering another leading institution in New York State demonstrates that the ART100 meets the operational and clinical demands of top-tier U.S. healthcare providers. Our focus remains on converting these high-profile evaluations into a sustainable commercial pipeline and further expanding our footprint across key U.S. markets.”
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that this evaluation builds upon the Company’s FDA clearance and ongoing commercial activity at other leading U.S. healthcare facilities, its U.S. commercial strategy, benefits and advantages of ART100 and conversion of high-profile evaluations into a sustainable commercial pipeline and further expansion of its footprint across key U.S. markets . These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
FAQ**
How does Inspira Technologies OXY B.H.N. Ltd. IINN plan to leverage the deployment of the ART100 system in New York's top hospitals to enhance its market presence in the U.S. medical device sector?
What specific metrics will Inspira Technologies OXY B.H.N. Ltd. IINN use to evaluate the success of the ART100 system deployment in U.S. academic medical centers?
How does Inspira Technologies OXY B.H.N. Ltd. IINN anticipate the integration of ART100 into clinical workflows will impact patient outcomes and hospital operations?
What risks and uncertainties outlined in the Form 20-F does Inspira Technologies OXY B.H.N. Ltd. IINN foresee potentially affecting its growth strategy following the ART100's U.S. market expansion?
**MWN-AI FAQ is based on asking OpenAI questions about Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN).
NASDAQ: IINN
IINN Trading
-2.18% G/L:
$0.58 Last:
47,279 Volume:
$0.594 Open:
